JP2014530009A - 異常細胞を標的とする多重特異性結合分子 - Google Patents

異常細胞を標的とする多重特異性結合分子 Download PDF

Info

Publication number
JP2014530009A
JP2014530009A JP2014533232A JP2014533232A JP2014530009A JP 2014530009 A JP2014530009 A JP 2014530009A JP 2014533232 A JP2014533232 A JP 2014533232A JP 2014533232 A JP2014533232 A JP 2014533232A JP 2014530009 A JP2014530009 A JP 2014530009A
Authority
JP
Japan
Prior art keywords
binding
proteinaceous
molecule
proteinaceous molecule
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014533232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530009A5 (enExample
Inventor
ラルフ アレキサンダー ウィレムセン，
ラルフ アレキサンダー ウィレムセン，
ヨーハン ルネ，
ヨーハン ルネ，
Original Assignee
エーピーオー‐ティー ビー．ヴイ．
エーピーオー‐ティー ビー．ヴイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーピーオー‐ティー ビー．ヴイ．, エーピーオー‐ティー ビー．ヴイ． filed Critical エーピーオー‐ティー ビー．ヴイ．
Publication of JP2014530009A publication Critical patent/JP2014530009A/ja
Publication of JP2014530009A5 publication Critical patent/JP2014530009A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014533232A 2011-09-29 2012-09-26 異常細胞を標的とする多重特異性結合分子 Pending JP2014530009A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161540920P 2011-09-29 2011-09-29
US61/540,920 2011-09-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017173519A Division JP2018046811A (ja) 2011-09-29 2017-09-08 異常細胞を標的とする多重特異性結合分子

Publications (2)

Publication Number Publication Date
JP2014530009A true JP2014530009A (ja) 2014-11-17
JP2014530009A5 JP2014530009A5 (enExample) 2017-01-19

Family

ID=47018432

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014533232A Pending JP2014530009A (ja) 2011-09-29 2012-09-26 異常細胞を標的とする多重特異性結合分子
JP2017173519A Pending JP2018046811A (ja) 2011-09-29 2017-09-08 異常細胞を標的とする多重特異性結合分子
JP2019211793A Pending JP2020058354A (ja) 2011-09-29 2019-11-22 異常細胞を標的とする多重特異性結合分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017173519A Pending JP2018046811A (ja) 2011-09-29 2017-09-08 異常細胞を標的とする多重特異性結合分子
JP2019211793A Pending JP2020058354A (ja) 2011-09-29 2019-11-22 異常細胞を標的とする多重特異性結合分子

Country Status (6)

Country Link
US (3) US11098115B2 (enExample)
EP (2) EP3388451A1 (enExample)
JP (3) JP2014530009A (enExample)
AU (3) AU2012316859A1 (enExample)
CA (1) CA2850291A1 (enExample)
WO (1) WO2013048243A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504903A (ja) * 2021-01-29 2024-02-02 中外製薬株式会社 細胞死が観察される組織において特異的に作用する分子

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091564A2 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
WO2014003552A1 (en) * 2012-06-26 2014-01-03 Apo-T B.V. Binding molecules targeting pathogens
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
TWI603980B (zh) * 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
US20190031785A1 (en) * 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CA3102254A1 (en) * 2018-06-04 2019-12-12 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2021263221A1 (en) * 2020-06-26 2021-12-30 Novather, Inc. Binding modulator
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
JP2025534663A (ja) * 2022-10-14 2025-10-17 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 治療薬の標的化送達のための組成物及び方法
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525016A (ja) * 1998-02-19 2003-08-26 エクサイト セラピーズ， インコーポレイテッド リンパ球活性化を調節するための組成物および方法
JP2005501517A (ja) * 2001-04-11 2005-01-20 中国科学院遺▲傳▼学研究所 環状一本鎖三重特異性抗体
JP2005504524A (ja) * 2001-06-28 2005-02-17 ドマンティス リミテッド 二重特異性リガンドとその利用
JP2009515897A (ja) * 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
JP2009524422A (ja) * 2006-01-25 2009-07-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子３
JP2010535032A (ja) * 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
JP2014505471A (ja) * 2010-12-27 2014-03-06 エーピーオー‐ティー ビー．ヴイ． アポトーシスを誘導する架橋ポリペプチド

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB601513A (en) 1946-02-06 1948-05-06 Koray Ltd Improvements in or relating to coated tissue especially paper and to coating compositions therefor
DE321017C (enExample) 1917-05-15 1920-05-11 Aloysius Petrus Van Leuven
US3687370A (en) 1971-01-18 1972-08-29 Instapak Corp Liquid mixing and dispensing apparatus
NL9001639A (nl) 1990-07-19 1992-02-17 Amc Amsterdam Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen.
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
NZ307633A (en) 1995-05-09 2000-01-28 Kreatech Biotechnology Bv Methods for the production of platinum-based linkers between labels and bio-organic molecules, for labelling bio-organic molecules, for detecting
EP0973785B1 (en) 1997-04-10 2003-12-03 Kreatech Biotechnology B.V. Trans-platinum compound, and diagnostic kit
PL196605B1 (pl) 1997-08-12 2008-01-31 Leadd Bv Sposób oznaczania zdolności transformującej, sposób oznaczania predyspozycji do przekształcania się w komórkę nowotworową, sposób oznaczania predyspozycji do dziedziczenia rodzajów raka, sposób oznaczania mutacji genu i diagnostyczny zestaw testowy
EP1124568B1 (en) * 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
EP1377667B1 (en) 2001-03-30 2008-11-19 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
JP4049297B2 (ja) 2001-06-11 2008-02-20 株式会社ルネサステクノロジ 半導体記憶装置
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
JP4213586B2 (ja) * 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
EP1442301A1 (en) 2001-11-09 2004-08-04 Kreatech Biotechnology B.V. Means and methods for the detection of immunoglobulin capable of binding to mycobacterium antigen
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
FR2837837B1 (fr) 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
WO2003089467A1 (en) 2002-04-19 2003-10-30 Leadd B.V. Fragments of apoptin
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US7820166B2 (en) * 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
JP2006523437A (ja) 2002-12-03 2006-10-19 アヴィデックス リミテッド レセプター複合体
CA2519528C (en) * 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
AU2004242845B2 (en) * 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
US20050026881A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
ES2296423B1 (es) * 2003-07-31 2009-03-16 Consejo Sup. Investig. Cientificas Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP4658967B2 (ja) 2003-12-24 2011-03-23 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
US20100062001A1 (en) 2004-06-09 2010-03-11 Technion Research & Development Antibodies for selective apoptosis of cells
EP1809669A2 (en) * 2004-10-01 2007-07-25 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
US20090208502A1 (en) 2005-12-20 2009-08-20 Ralph Alexander Willemsen Apoptosis-inducing protein complexes and therapeutic use thereof
JP2009521474A (ja) * 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
CA2682093A1 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US8568717B2 (en) 2008-04-03 2013-10-29 Vib Vzw Single domain antibodies capable of modulating BACE activity
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2009299794B2 (en) * 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2504360B1 (en) * 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
EP2504358B1 (en) 2009-11-24 2016-10-19 ChronTech Pharma AB T cell receptors specific for immunodominant ctl epitopes of hcv
WO2011085473A1 (en) 2010-01-13 2011-07-21 Linda Penn Treating cancer with statins and compounds having dipyridamole activity
US20120123218A1 (en) 2010-11-16 2012-05-17 JPWaVe BV Methods and means for clinical investigations
DK2658872T3 (da) 2010-12-27 2020-10-12 Apo T B V Polypeptid, der binder aberrerende celler og inducerer apoptose
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
WO2014003552A1 (en) 2012-06-26 2014-01-03 Apo-T B.V. Binding molecules targeting pathogens

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525016A (ja) * 1998-02-19 2003-08-26 エクサイト セラピーズ， インコーポレイテッド リンパ球活性化を調節するための組成物および方法
JP2005501517A (ja) * 2001-04-11 2005-01-20 中国科学院遺▲傳▼学研究所 環状一本鎖三重特異性抗体
JP2005504524A (ja) * 2001-06-28 2005-02-17 ドマンティス リミテッド 二重特異性リガンドとその利用
JP2009515897A (ja) * 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
JP2009524422A (ja) * 2006-01-25 2009-07-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子３
JP2010535032A (ja) * 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
JP2014505471A (ja) * 2010-12-27 2014-03-06 エーピーオー‐ティー ビー．ヴイ． アポトーシスを誘導する架橋ポリペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEGAL, DM., ET AL.: "Introduction: bispecific antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 248, JPN6016025423, 2001, pages 1 - 6, ISSN: 0003349771 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504903A (ja) * 2021-01-29 2024-02-02 中外製薬株式会社 細胞死が観察される組織において特異的に作用する分子

Also Published As

Publication number Publication date
AU2012316859A1 (en) 2014-04-17
EP2760892A1 (en) 2014-08-06
JP2020058354A (ja) 2020-04-16
JP2018046811A (ja) 2018-03-29
US11098115B2 (en) 2021-08-24
WO2013048243A1 (en) 2013-04-04
US20140227273A1 (en) 2014-08-14
US20250115662A1 (en) 2025-04-10
AU2017248425A1 (en) 2017-11-02
AU2020200888A1 (en) 2020-02-27
CA2850291A1 (en) 2013-04-04
AU2017248425B2 (en) 2019-11-14
EP3388451A1 (en) 2018-10-17
US20210355209A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
US20250115662A1 (en) Multi-specific binding molecules targeting aberrant cells
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
US11578126B2 (en) Chimeric antigen receptor (CAR) comprising a CD19-binding domain
AU2010299895B2 (en) Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
WO2020017479A1 (ja) 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
CN111699201B (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
WO2022222910A1 (zh) 靶向gprc5d的抗体及其用途
WO2022247795A1 (zh) 靶向Claudin18.2的纳米抗体及其用途
WO2022111405A1 (zh) 靶向Claudin18.2的抗体及其用途
WO2024001470A1 (zh) 靶向b7-h3的抗体及其用途
Hayashi et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
JP2024012258A (ja) Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体
KR102829757B1 (ko) 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
EP4606823A1 (en) Synthetic t cell receptor antigen receptor specifically binding to lilrb4 and use thereof
WO2023163087A1 (ja) 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬
US20250136695A1 (en) Development of novel pdl1 single-domain antibody
NZ739019A (en) Multi-specific binding molecules targeting aberrant cells
WO2024239143A1 (zh) 工程化细胞及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161005

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170509